Ascendis Pharma A/S ASND
225.60
(5.10)
(2.21%)
as of 25 Sep
- Market cap
- $15.7B
- P/E
- 16.3×
Follow ASND
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 118.44% | 311.60% | 172.80% | 164.31% |
+8 more TTM periods Free account |
|
| 44.34% | 33.40% | (18.76%) | (19.99%) | ||
ROIC |
15.07% | (1.01%) | (91.65%) | (82.72%) | |
Return on Tangible Assets |
69.94% | 375.74% | (122.55%) | (164.00%) | |
Average Days of Receivables |
78.46 | 84.24 | 79.93 | 86.95 | |
Free Cash Flow per Share |
6.02 | 0.80 | 0.85 | (1.97) | |
Free Cash Flow |
387.49 | 49.14 | 51.38 | (119.66) | |
Capital Expenditures |
(16.61) | (17.89) | (9.60) | (6.37) | |
Piotroski F-Score |
7.00 | 6.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
12.88% | 2.93% | 4.07% | (8.22%) | |
Accounts Receivable Turnover |
6.09 | 6.41 | 4.40 | 6.35 | |
Accounts Payable Turnover |
0.93 | 1.21 | 1.04 | 1.09 | |
Inventory Turnover |
0.30 | 0.32 | 0.32 | 0.30 | |
Average Days of Payables |
416.48 | 306.79 | 348.63 | 351.91 | |
Days of Inventory on Hand |
1,244.71 | 1,227.11 | 1,159.56 | 1,352.22 | |
Tax Rate |
6.93 | (3.91) | 0.07 | 0.04 | |
Research and Development Expense of Revenue |
27.05% | 32.23% | 42.16% | 46.48% | |
Selling, General and Administrative Expense of Revenue |
54.53% | 58.33% | 63.58% | 61.85% | |
Share Based Compensation of Revenue |
11.39% | 14.05% | 16.13% | 17.71% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.47 | 0.12 | (0.24) | 0.44 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.12 | 0.17 | |
Capex/Depreciation |
(0.82) | (0.89) | (0.48) | (0.32) | |
Revenue per Share |
18.84 | 16.16 | 13.44 | 11.89 | |
Operating CF per Share |
6.28 | 1.09 | 1.01 | (1.86) | |
Capex per Share |
(0.26) | (0.29) | (0.16) | (0.10) | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | |
Net Profit Margin |
71.20% | 58.00% | (31.67%) | (35.30%) |
Columns are period end dates